Leading the way to safer medication
 Crosscheck  Recommender

Brigatinib

Brand names: ALUNBRIG

Therapeutic Indications

Brigatinib is indicated for:

Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Irrespective of gender only Adults (18 years old or older)

Brigatinib is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

Brigatinib is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 90-180 mg once daily

Contraindications

Active ingredient Brigatinib is contraindicated in the following cases: